Skip to content

Earnings call

Indoco Remedies Q4 FY25 earnings call

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company expects to manufacture 25% fewer batches this year on a much higher expected manufacturing base as part of its master manufacturing plan. The company planned manufacturing improvements across all 4 solid oral manufacturing sites. Warren Remedies Private Limited had a negative impact in its first 2 years from infrastructure investment, facility running costs and television, radio and digital media advertising costs; Indoco Remedies Limited had expected this impact. With Perrigo and several other players, Indoco Remedies Limited has over 60% of the market in U.K. for paracetamol. The company has steadily built good market share across many geographies in large volume solid oral products for its European markets, a business it entered more than 20 years ago.

The numbers management gave

Results

  • Warren Remedies Private Limited had a negative impact in its first 2 years from infrastructure investment, facility running costs and television, radio and digital media advertising costs; Indoco Remedies Limited had expected this impact.
    Show source
    The investments in the infrastructure and the cost of running the facility as well as the costs associated with advertising on television, radio as well as digital media have taken their toll, and we had expected this kind of a negative impact in WRPL for the first 2 years.
  • Product Cylopam added INR25 crores incrementally in 1 year alone.
    Show source
    Happy to share that the product added INR25 crores incrementally in 1 year alone.
  • Cylopam had a turnover of INR178 crores at PTR rates as per IQVIA.
    Show source
    And today, as per IQVIA, we are clocking a turnover of INR178 crores at PTR rates.
  • Standalone net revenues for the fourth quarter FY '24- '25 were INR3,411 million compared to INR4,351 million for the same quarter last year.
    Show source
    The standalone net revenues of the company for the fourth quarter FY '24- '25 are at INR3,411 million compared to INR4,351 million for the same quarter last year.
  • Standalone revenues for the year were INR14,948 million compared to INR17,620 million.
    Show source
    For the year, standalone revenues are at INR14,948 million as against INR17,620 million.
  • Consolidated net revenues for the fourth quarter '24-'25 were INR3,839 million compared to INR4,391 million for the same quarter last year.
    Show source
    Consolidated net revenues for the company for the fourth quarter '24-'25 are at INR3,839 million compared to INR4,391 million for the same quarter last year.
Show 40 more statements

Results

  • Consolidated revenues for the year were INR16,413 million compared to INR17,882 million.
    Show source
    Page 4 of 19 Indoco Remedies Limited May 22, 2025 For the year, consolidated revenues are at INR16,413 million as against INR17,882 million.
  • Standalone EBITDA to net sales for Q4 FY25 was 1% at INR35 million compared to 13.2% at INR574 million.
    Show source
    Standalone EBITDA to net sales for the quarter is 1% at INR35 million compared to 13.2% at INR574 million.
  • Standalone EBITDA to net sales for the year was 8.6% at INR1,280 million compared to 14.6% at INR2,580 million.
    Show source
    Standalone EBITDA to net sales for the year is 8.6% at INR1,280 million compared to 14.6% at INR2,580 million.
  • Consolidated EBITDA to net sales for Q4 FY25 was minus 0.2% at minus INR0.8 million compared to 11.1% at INR489 million for the same quarter last year.
    Show source
    Consolidated EBITDA to net sales for the quarter is minus 0.2% at minus INR0.8 million compared to 11.1% at INR489 million for the same quarter last year.
  • Consolidated EBITDA to net sales for the year was 6% at INR993 million compared to 13.7% at INR2,443 million.
    Show source
    Consolidated EBITDA to net sales for the year is 6% at INR993 million compared to 13.7% at INR2,443 million.
  • Domestic formulation business revenues for Q4 FY25 were INR1,851 million compared to INR1,911 million.
    Show source
    Revenues from domestic formulation business for the quarter are at INR1,851 million as compared to INR1,911 million.
  • International Formulations business revenues for Q4 FY25 were INR1,104 million compared to INR2,140 million.
    Show source
    On the international business front, revenues from International Formulations business are at INR1,104 million compared to INR2,140 million.
  • Revenues from regulated markets for Q4 FY25 were INR786 million compared to INR1,458 million.
    Show source
    Revenues from regulated markets for the quarter are at INR786 million as against INR1,458 million.
  • Revenues from U.S. business for Q4 FY25 were INR308 million compared to INR675 million.
    Show source
    Revenues from U.S. business for the quarter are at INR308 million as against INR675 million.
  • Revenues from Europe for Q4 FY25 were INR466 million compared to INR765 million.
    Show source
    Those for Europe for the quarter are at INR466 million as against INR765 million.
  • Revenues from South Africa, Australia and New Zealand for Q4 FY25 were INR12 million compared to INR18 million.
    Show source
    And for South Africa, Australia and New Zealand, they are INR12 million against INR18 million.
  • Emerging markets revenues for Q4 FY25 were INR318 million compared to INR682 million, and API business revenues were INR409 million compared to INR217 million.
    Show source
    Revenues from emerging markets for the quarter are INR318 million as against INR682 million and revenues from API business for the quarter INR409 million as against INR217 million.
  • Revenues from services, AnaCipher and Indoco Analytical Solutions for Q4 FY25 were INR47 million compared to INR83 million.
    Show source
    Revenues from services, AnaCipher and Indoco Analytical Solutions are at INR47 million as against INR83 million.
  • The company spent close to INR4 crores per quarter on remediation expenses for all 4 quarters this year.
    Show source
    Aditi Kare Panandikar: So we spent close to INR4 crores per quarter on remediation expenses.
  • International business revenue was 48% of the previous year's revenue in this year.
    Show source
    If you look at this year, therefore, and you study the performance of -- for Page 7 of 19 Indoco Remedies Limited May 22, 2025 revenues, the international business has -- is actually at 48% compared to the previous year.
  • Other expenses were close to INR140 crores, and Aditi Kare Panandikar was hopeful of arresting them at INR120 crores in another quarter.
    Show source
    As of now, I think we are doing close to INR140 crores on other expenses, but I am hopeful in another quarter to be able to arrest it at INR120 crores.
  • U.S. market total revenues were INR286 crores in '23-'24, including close to INR200 crores in revenue from the sterile plant, compared with INR42 crores from the sterile plant this year.
    Show source
    Aditi Kare Panandikar: So the last part of your question – so coming to U.S. business, U.S. last year, total revenues for U.S. market in '23-'24 were INR286 crores, of which there were substantial amount coming from sterile, close to INR200 crores was revenue from the sterile plant alone, which this year is only INR42 crores.
  • Oral solids revenue was INR52 crores last year and INR81 crores now.
    Show source
    Whereas oral solids, which were only INR52 crores last year are at INR81 crores now.
  • Stomatologicals grew by 2.5% in the fourth quarter as per IQVIA, compared with the market's minus 1.4%.
    Show source
    And just to give you some numbers, we have -- for the fourth quarter, our stomatologicals has grown by 2.5% as per IQVIA, whereas as per the market is minus 1.4%.
  • Consolidated India business performance grew at more than 8.5%, at par with or better than industry growth.
    Show source
    If you look at the consolidated picture of India business performance, you will see that we have grown at more than 8.5%, which is at par or even better than the industry growth.
  • The company incurred close to INR4 crores every quarter on remediation, including remediation partner costs and improvements at the site.
    Show source
    Aditi Kare Panandikar: So we have been incurring close to INR4 crores every quarter on remediation, which includes costs of the remediation partners, certain improvements to be done at the site, etcetera, etcetera.
  • The company said 99% of the master manufacturing plan-related impact had passed.
    Show source
    99% is over.
  • At Indoco Remedies Limited, new products' contribution to total growth is in excess of 4.5%, compared with the industry average of 2.5%.
    Show source
    Coming to Indoco Remedies Limited. today, at IRL, our contribution of new products to total growth is in excess of 4.5%, which is way higher than the industry average of 2.5%.
  • In its first year, OTC had limited sales success, while Nielsen numbers indicated good growth at the tertiary demand stage.
    Show source
    The first year of OTC has given us limited success by way of sales and the Nielsen numbers indicate a good growth at the tertiary demand stage.
  • During the year, particularly in the second half, many of Indoco Remedies Limited's solid oral sites had to take planned shutdowns for the improvements at the same time, impacting supply of products to Europe and U. S. and the company's results.
    Show source
    This has impacted supply of product to Europe and U. S. and this has shown in our results.
  • Performance for the year was affected by Warren Remedies Private Limited's impact on consolidated numbers, the master manufacturing plan and the resulting lack of sufficient solid oral products to sell in Europe and U.S., as well as the warning letter's impact on the U.S. business.
    Show source
    And last but not the least, the impact of the warning letter on the U.S. business has taken its own toll on the company's performance for this year.
  • Vitamins, minerals, nutrients, gastrointestinals and urology therapeutic segments performed well during Q4 FY25 compared to the same quarter last year.
    Show source
    Major therapeutic segments like vitamins, minerals, nutrients, gastrointestinals and urology performed well during the quarter as compared to the same quarter last year.
  • The company said planned and other shutdowns prevented optimal use of its manufacturing plants during the year, while the fixed costs at its active manufacturing sites were growing; the mismatch between revenues and cost structure was largely responsible for the performance.
    Show source
    So typically, this is a mismatch between the revenues and the cost structure that we are holding, and that is largely responsible.
  • The company incurred additional costs at the sterile site because of the warning letter and remediation costs.
    Show source
    Also with the warning letter and the remediation costs, there have been several additional costs at the sterile site as well.
  • The company said remediation work on products contributed to increased stores and spares expenses, and synchronizing products across sites required spares at various manufacturing sites.
    Show source
    So stores and spares, a lot of it has got to do with the remediation and therefore, some of the work that we've had to do on products.
  • The company said its respiratory and anti-infective categories, in which it has a large stake, grew faster than the market.
    Show source
    Our another category where we are very -- we have a large stake, which is respiratory, where the market has gr own slower than us and so is anti -infective.
  • The company attributed the impact on its numbers largely to a couple of its toothpastes now being sold by Warren Remedies as OTC.
    Show source
    Regards the impact seen on our numbers, that is largely because a couple of our toothpaste, which now are sold by Warren Remedies as OTC.
  • The company changed its supply chain, which took almost a year to catch up and return to normal levels.
    Show source
    And it has taken us almost a year to catch up and come back to normal levels.
  • The company saw growth in sales of the two toothpastes that went OTC in IQVIA for the first time in April.
    Show source
    So the last month, I think month of April is the first time we are seeing again growth in the sales of the two toothpastes, which have gone OTC in IQVIA.
  • Master manufacturing plan across all its solid oral sites had a great impact on the company's performance. Replaced by a later filing.
    Show source
    Secondly, there has been a great impact on the company's performance because of the master manufacturing plan, which we have put in place across all our solid oral sites.

Money and capital

  • The company has invested close to about INR280 crores in Warren Remedies for its toothpaste business, intermediates and API manufacturing, plants, marketing setup and distribution network.
    Show source
    So both put together, till now, we have invested close to about INR280 crores for both the plants and certain activities on the marketing setup and distribution network.
  • The company had a total short-term loan of INR20 crores and long-term loan of INR330 crores overall.
    Show source
    So total short-term loan, which is there is INR20 crores and long-term loan is INR330 crores overall.
  • The company had close to about INR400 crores as long-term debt and about INR211 crores as short-term debt.
    Show source
    While in Indoco, we have close to about INR400 crores as a long-term debt and about INR211 crores as a short-term debt.
  • Debt level was about INR960 crores.
    Show source
    So all put together, close to about -- debt level is about INR960 crores.
  • Capex investment over the last couple of years was close to INR200-plus crores, plus what it invested in Warren Remedies; both put together, the investment was more than INR300 crores.
    Show source
    So both put together more than INR300 crores.

What it expects ahead

What management expects

  • The company expects to manufacture 25% fewer batches this year on a much higher expected manufacturing base as part of its master manufacturing plan.
    Show source
    And all in all, we expect this year on a much higher expected manufacturing base to actually manufacture 25% less batches.
  • The company expects its solid oral business to ramp up in '26, '27 and '28 as more solid orals for which it already has tentative approvals go off patent.
    Show source
    And as we get into '26, '27, '28, where more solid orals would go off patent for which we already have tentative approvals, I expect solid oral business to ramp up .
  • Normal base for Europe used to be around INR300 crores; the business was impacted this year by inability to supply solid orals, and the company expects it to return to the INR300 crore level in the coming year.
    Show source
    And I exp ect it to go back to the INR300 crore level in the coming year.
  • The company said it would be back on its feet to the extent of 50% regarding the warning letter.
    Show source
    Regarding warning letter, to the extent of 50%, I think we would be on our feet back.
  • The company plans to keep R&D investment at around 5% of top line for the next couple of years, and it does not expect the investment to come below that, despite being choosier about products.
    Show source
    But it will still stay at around 5% of top line.
  • The company expects resumption of supplies from its sterile plant in the second quarter this year following the latest positive stroke from U.S. FDA, with a pickup gradually through the last quarter.
    Show source
    Coming to sterile, as I said, with this latest positive stroke coming from U.S. FDA, we expect resumption of supplies in the second quarter this year.
Show 5 more statements

What management expects

  • The company expects a step-up jump in its U.S. business from the second half of this year.
    Show source
    Page 9 of 19 Indoco Remedies Limited May 22, 2025 Sudarshan Padmanabhan: And U.S., I mean, we would basically see a step-up jump from the second half of this year.
  • The company does not expect losses from Warren Remedies to further increase, after investments in advertising, people and infrastructure as it moves to OTC.
    Show source
    So I don't expect the losses from Warren Remedies to further increase.
  • The company expects improvement from here, as continuing losses or a return to profit depend on revenue and arresting costs.
    Show source
    So net-net, I think you will only see improvement from here.
  • The company expects Warren Remedies' base sales to grow at least in double digits.
    Show source
    And from here on, I expect Warren Remedies base sales to also grow in a good fashion, at least in double digits.
  • The company will grow. Replaced by a later filing.
    Show source
    Aditi Kare Panandikar: We will grow.

What it is building and selling

Projects and capacity

  • The company planned manufacturing improvements across all 4 solid oral manufacturing sites.
    Show source
    We had, therefore, planned this kind of improvement across all our 4 manufacturing sites of solid orals.
  • The company invested in people, infrastructure and the supply chain to service the OTC segments and manufacture cosmetic licensed products.
    Show source
    And in order to service the OTC segments properly as well as to manufacture cosmetic licensed products, we have invested in people, infrastructure as well as the supply chain.
  • The company invested in manufacturing sites to improve compliance, enable better technology, reduce manpower used in manufacturing, packing, processing and supply, and increase batch sizes for better returns.
    Show source
    Having acquired this market share, we felt it proper to invest in our manufacturing sites to make them more compliant going forward in order to enable us to run better technology, reduce manpower used in manufacturing, packing, processing and supply as well as increase batch sizes to get better returns.
  • Master manufacturing plan aligns the manufacturing of several large molecules across various locations and has increased batch sizes to control other expenses.
    Show source
    As part of the master manufacturing plan, we have aligned manufacturing of several large molecules at various locations.
  • The company intends to bring down the manpower employed at various sites as part of its master manufacturing plan.
    Show source
    We intend to bring down the manpower employed at various sites.

Demand and pricing

  • With Perrigo and several other players, Indoco Remedies Limited has over 60% of the market in U.K. for paracetamol.
    Show source
    For example, we have with our partners, Perrigo and several other players, over 60% of the market in U.K. for paracetamol.
Show 3 more statements

Demand and pricing

  • The company has over 80% of the market in Germany and 35% of the market in U.S. for allopurinol formulations.
    Show source
    When it comes to allopurinol formulations, we have over 80% of the market in Germany, 35% of the market in U.S. and several other geographies.
  • Warren Remedies has had volume and value growth in the market in excess of double digits as per Nielsen, and Indoco Remedies Limited expects this to create good demand.
    Show source
    But just to quote as per Nielsen, which is a report we now look at to study the health of our toothpaste, we have got good volume and value growth in the market in the excess of double digits.

Segments

  • The company has steadily built good market share across many geographies in large volume solid oral products for its European markets, a business it entered more than 20 years ago.
    Show source
    Meanwhile, mostly for our European markets, a business which we got into more than 20 years ago, we have steadily built good market share across many geographies for large volume solid oral products.

Risks, rules and outside factors

Risks and disputes

  • U.S. FDA inspected Indoco Remedies Limited's sterile plant in Goa in February 2023 and classified it OA I; a surprise audit in June 2024 resulted in a warning letter.
    Show source
    As you know, we were inspected first by U.S. FDA in February 2023, after which we were classified OA I. Thereafter, there was a surprise audit in June 2024, which has resulted in the warning letter.
  • The company was to be prepared with remediation actions by November '24, but U.S. FDA's early audit in June meant several updates were still pending with FDA and resulted in a warning letter.
    Show source
    On my earlier calls, I have explained that while we were to be prepared with our remediation actions by November Page 3 of 19 Indoco Remedies Limited May 22, 2025 '24, FDA's early audit in June meant that several of our updates were yet pending with the FDA, and therefore, we ended up getting a warning letter.
  • The warning letter on Indoco Remedies Limited's sterile plant meant several products supplied to the U.S. market could no longer be supplied because many were manufactured and packed under aseptic conditions and updates were still pending.
    Show source
    Warning letter on the sterile plant meant that several of the products we were supplying to U.S. market could no longer be supplied as many of them were manufactured and packed under aseptic conditions, and our updates were yet pending.
  • EMA's audit of Indoco Remedies Limited's Plant II in Goa, its sterile facility under warning letter, went successfully.
    Show source
    Plant II in Goa, our sterile facility, which is under warning letter, was earlier inspected by EMA or the European Medicine Agency, and the audit has gone very successfully.
  • The EMA audit of Indoco Remedies Limited's Plant II in Goa had no criticals, no majors and a few minors.
    Show source
    We have no criticals, no majors and a few minors.

Outside factors

  • The company said cost of goods and material costs are consistently going up, and increasing manufacturing efficiency is the only way to stay competitive.
    Show source
    While cost of goods and material costs are consistently going up, the only way to stay competitive is to increase efficiency in manufacturing.
Show 2 more statements

Outside factors

  • Globally, pharmaceutical products are facing pricing pressure due to patent cliff or government intervention to provide medicines at affordable prices, calling for quality products to be supplied at cheaper and competitive prices. Replaced by a later filing.
    Show source
    As you all know, globally, pharmaceutical products are witnessing pricing pressure either due to patent cliff or government intervention to provide medicines at affordable prices.

Rules and policy

  • The company received positive communication from U.S. FDA allowing it to restart a couple of lines in Plant II.
    Show source
    My team at Plant II is extremely enthused with this audit, and it shows that we are on the right track towards providing remediation even to U.S. Another good news to be shared is as recently as about 24 hours ago, we have also received some positive communication from U.S. FDA, which allows us to restart a couple of our lines in Plant II.

Everything else said on the call

What management stressed

  • The company has initiatives underway to increase digitization and reduce other operating costs and control capex going forward. Replaced by a later filing.
    Show source
    Apart from that, across the organization, various initiatives to increase digitization, digitalization to reduce other operating costs to control capex going further are in full swing.

Group structure

  • The company formed Warren Remedies Private Limited as a 100% subsidiary earlier in the beginning of the year to take products over the counter.
    Show source
    As you know, earlier in the beginning of the Page 2 of 19 Indoco Remedies Limited May 22, 2025 year, we formed a 100% subsidiary, Warren Remedies Private Limited, with an intention to take products over the counter.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    Sudarshan Padmanabhan: Utilization across the plant given several… Page 8 of 19 Indoco Remedies Limited May 22, 2025 Aditi Kare Panandikar: Yes, yes, yes, yes.

    Answer, aditi panandikar

    So because of this restructuring of products across sites, what we have achieved really is bringing down the complexity of the product mix at each unit and in turn, increasing capacity because then that means fewer changeovers, better efficiency in testing and several other things. So quite frankly, I think your question was about how much revenues can we get from this kind of a turnover. So even of a steady year like the earlier year when we did not have manufacturing problems, we were very confident on multiplying by at least 2.5x our top line from this business. So I think last year, other than India business was at close to INR800 crores, if I'm not mistaken. And we can easily look at up to INR2,000 crores with this revenue -- with this capacity, sorry.

  2. Question

    And ma'am, with respect to normalization in the international business, I mean, how do we see both the U.S. and European business gathering momentum? And in the light of things while margins have been a little difficult for us to -- or anybody to kind of put a precise number, how do we see the margins expanding, say, in the near and medium term?

    Answer, aditi panandikar

    Aditi Kare Panandikar: So the last part of your question – so coming to U.S. business, U.S. last year, total revenues for U.S. market in '23-'24 were INR286 crores, of which there were substantial amount coming from sterile, close to INR200 crores was revenue from the sterile plant alone, which this year is only INR42 crores. Whereas oral solids, which were only INR52 crores last year are at INR81 crores now. So solid oral contribution has really gone up. And as we get into '26, '27, '28, where more solid orals would go off patent for which we already have tentative approvals, I expect solid oral business to ramp up . This business is coming from Plant I incidentally, which has also been revamped as part of the master manufacturing plan. Coming to sterile, as I said, with this latest positive stroke coming from U.S. FDA, we expect resumption of supplies in the second quarter this year. And gradually, you will see a pickup till the last quarter.

    Answer, aditi panandikar

    Coming to Europe, our normal base for Europe used to be around INR300 crores. And this year, it got impacted because of inability to supply, etcetera, of solid orals. And I exp ect it to go back to the INR300 crore level in the coming year. I hope that answers your question. Page 9 of 19 Indoco Remedies Limited May 22, 2025 Sudarshan Padmanabhan: And U.S., I mean, we would basically see a step-up jump from the second half of this year.

  3. Question

    So it would be more of an FY '27 rather than an FY '26 kind of a scenario.

    Answer, aditi panandikar

    Aditi Kare Panandikar: Yes. This is a year of us coming back to our normalized values of the prior year.

  4. Question

    Sudarshan Padmanabhan: Sure. And ma'am, you had given some color on the costs coming down by about INR20 crores a quarter. What is the kind of margins that one should expect because the margins have come up quite sharply from where it was. So some color on that in the near term as well as long term.

    Answer, aditi panandikar

    Aditi Kare Panandikar: So like I said, when you have to run 8 manufacturing sites, all having fixed costs, but you're able to efficiently supply only out of 2, I think you can do your own math, and that is what has really put the pressure on margins. Therefore, I would like to wait for another quarter for numbers to talk for themselves because it's a dynamic between both. It is not sufficient for us to complete our restructuring of manufacturing. We also should be able to supply from those sites very effectively. As of now, we have sufficient orders in hand and feel confident that we'll be able to do that. But I would like maybe Q2 will be the right quarter for you to show this upside. And then from there, I will be more confident telling you about improvement after that.

  5. Question

    Sudarshan Padmanabhan: Ma'am, on the domestic business, I mean, we have taken a lot of initiatives in the past, I mean, reorganizing the field force, etcetera. Where do we see or when do we start seeing the benefits of that because we still continue to lag the IPM cost?

    Answer, aditi panandikar

    Aditi Kare Panandikar: So let me just quickly correct you on that because when you compare with IPM, we might be lagging. But vis-a-vis our covered market, we are doing very well. So as you know, we are one of the companies which has got a very high stake in acute and sub- chronic. And just to give you some numbers, we have -- for the fourth quarter, our stomatologicals has grown by 2.5% as per IQVIA, whereas as per the market is minus 1.4%. Our another category where we are very -- we have a large stake, which is respiratory, where the market has gr own slower than us and so is anti -infective. So if you look at our performance in India, within our -- within the zone where we operate and are present, we have done pretty well. Regards the impact seen on our numbers, that is largely because a couple of our toothpaste, which now are sold by Warren Remedies as OTC.

    Answer, aditi panandikar

    And I've explained this earlier, we have changed the supply chain. And it has taken us almost a year to catch up and come back to normal levels. So the last month, I think month of April is the first time we are seeing again growth in the sales of the two toothpastes, which have gone OTC in IQVIA. Page 10 of 19 Indoco Remedies Limited May 22, 2025 So what is suffering really is the projection. If you look at the consolidated picture of India business performance, you will see that we have grown at more than 8.5%, which is at par or even better than the industry growth.

    Answer, aditi panandikar

    Aditi Kare Panandikar: No, I think by and large, I can just give you the way you could look at it is IRL is standalone, and we also give consolidated results. So in consolidation, we have two entities. One is Warren Remedies Private Limited, which manufactures and sells OTC toothpaste of cosmetic license, and it also manufactures certain API stacking materials for us. So there has been a good investment in that. The second entity is FPP, which is the company we acquired in U.S. to create our front end. So both these entities have impacted our margins. But at this stage, I'm not -- we have not really giving out those numbers, but safe to say that the impact coming from both these entities on the consolidated numbers is expected to go down this year.

    Answer, aditi panandikar

    But if the main entity where we had major constraints because of product availability and the U.S. FDA warning letter, if that gets corrected, this impact is not going to really hurt our numbers too much. Maulik: Understood. Understood. And 2 clarifications. You mentioned the remediation cost, which we have been incurring. Can you please repeat it?

    Answer, aditi panandikar

    Aditi Kare Panandikar: So we have been incurring close to INR4 crores every quarter on remediation, which includes costs of the remediation partners, certain improvements to be done at the site, etcetera, etcetera. Maulik: Okay. Okay. And is my understanding correct that by July, August, the site would be ready and any time inspection could be due after that?

    Answer, aditi panandikar

    Aditi Kare Panandikar: We would hope we have to wait and see. The site will be ready after August.

    Answer, aditi panandikar

    Aditi Kare Panandikar: Yes, yes, yes. So thank you for reminding me. I had kind of painted a picture of Q4. And as you have seen, it has not been a great quarter on margins at all. And yes, I believe we are at the rock bottom of the losses. And from here on, I don't expect any further deterioration.

  6. Question

    Ankit Gupta: But losses will continue at least for a quarter or 2?

    Answer, aditi panandikar

    Aditi Kare Panandikar: Like I said, losses -- continuing losses or coming out into profit is a function of both revenue and arresting of costs. And most -- out of the 3 factors which have impacted us, the master manufacturing plan related impact has now almost gone. 99% is over. Regarding warning letter, to the extent of 50%, I think we would be on our feet back. And regarding Warren Remedies, as I explained, when you go OTC and you start pumping into ad expenditure, investment, people, the kind of infra we put up, we were anyway planning to have a couple of years of muted. So I don't expect the losses from Warren Remedies to further increase. So net-net, I think you will only see improvement from here.

  7. Question

    Ankit Gupta: And ma'am on the European site, you had indicated that post our master manufacturing plan, we'll start seeing growth even from FY '24 numbers. FY '25, again, we have seen degrowth in numbers. But in FY '26, we'll start seeing growth from FY '24 EU numbers. So like what kind of growth are we expecting in the European market for next financial year?

    Answer, aditi panandikar

    Aditi Kare Panandikar: So like I said, at this point, we should look at doing numbers equivalent to or better than the previous year.

  8. Question

    Ankit Gupta: Okay. So FY '24 should be considered as the base and on that, we should be flat or should grow somewhat.

    Answer, aditi panandikar

    Aditi Kare Panandikar: We will grow. We will grow. But having -- you must understand coming out of such a period, it's not easy for us to talk of growth. Like I said, let the numbers talk for themselves. Page 12 of 19 Indoco Remedies Limited May 22, 2025 Ankit Gupta: Sure, sure.

  9. Question

    And on the India growth side, India business growth, so except for -- if you remove the Warren Remedies and our base business, if you consider what kind of growth should we expect for next financial year? And what are our plans for launching new products? And how do you see the scale up in those new products?

    Answer, aditi panandikar

    Aditi Kare Panandikar: Yes. So 3 questions. Let me start with Warren Remedies because you said keep Warren Remedies aside. But just to quote as per Nielsen, which is a report we now look at to study the health of our toothpaste, we have got good volume and value growth in the market in the excess of double digits. So I expect this to create good demand. And from here on, I expect Warren Remedies base sales to also grow in a good fashion, at least in double digits. Coming to Indoco Remedies Limited. today, at IRL, our contribution of new products to total growth is in excess of 4.5%, which is way higher than the industry average of 2.5%.

    Answer, aditi panandikar

    So most of our new launches are doing very well. This quarter, for example, we have launched a product Drotitec and its brand extension among several others. And on new products, certain products like Noxa, we continue to be market leaders. With NINAF, we stay #2, but most of our new products have done very well. Coming to IRL standalone without Warren, without new products, if you look at our legacy products without new products, then most of our legacy products other than Febrex Plus, which has got impacted from market. Market of Febrex Plus is, I think, down minus 4%. We are flat.

    Answer, aditi panandikar

    So -- and azithromycin, which is our brand ATM, market is also down, and we are equivalently at the same level. So other than these 2 brands, almost all other products of Indoco have shown very healthy double -digit growth. Cyclopam, as I said, has grow n by 25%. If you look at a product like Cital also, it is growing in double digits for the year. And … Ankit Gupta: So on the Indian business, can we expect -- including the new products and the higher sales of new products that we have launched in FY '24 and '25, can we expect 12%, 15% of growth in the domestic market?

    Answer, aditi panandikar

    Aditi Kare Panandikar: So we will attempt to do much better than the market. Okay.

  10. Question

    Ankit Gupta: Okay. And on Warren Remedies, do you think we can breakeven next year or FY '27 is the only year we can breakeven there?

    Answer, aditi panandikar

    Aditi Kare Panandikar: So there are 2 parts to it. Some of it, very little is towards remediation because most of the capex on remediation was done in the earlier year also. So most of the capex spend this year has been for putting a master plan in place and expanding capacity. For the numbers, I will hand over to Pramod, if he'd like to give. Pramod Ghorpade So with regards to capex, as madam also mentioned about our investment during the last couple of years and particularly last year when we invested heavily. So overall capex investment was close to about INR200-plus crores, plus what we have invested in Warren. So both put together more than INR300 crores.

    Answer, aditi panandikar

    While your question about the plan for this particular financial year '24 -- '25-'26, we don't intend to spend much on capex. We have controlled capex. And most of the capex work is almost at finishing stage in all sites. So we don't anticipate much capex, except the routine maintenance capex.

Show 3 more questions
  1. Question

    Raja Kumar: Per annum. Okay. Yes. And the next question is, I see that the rating agency is currently kind of downgraded your credit rating. So, I mean, what is the plan? Do you have a plan to get your rating up? Or this is something not going to happen in the short to medium term? Page 14 of 19 Indoco Remedies Limited May 22, 2025 Sundeep Bambolkar: Yes.

    Answer, sundeep bambolkar

    This is Sundeep Bambolkar. See, when we went through a similar patch in 2016, U.S. FDA and U.K. MHRA plant issues, we had similar problems and the rating agency had downgraded us that time also. But immediately, when we had a good performance ever since 2018, right up to '24 now, we have always been A1+ in the short term and AA- on the long term, which is the topmost rating company of our size can have. And subsequently, we have been having excellent borrowing rates. So this is a limited period phenomenon, which we have to face. And as soon as we are out of it, they will come down and upgrade us once again.

  2. Question

    Raja Kumar: Okay. And sir, just continuing on the same question, given that you have a significant borrowing cost, is there a plan to organically only reduce this? Or you have any other monetization plans to reduce the debt?

    Answer, sundeep bambolkar

    Sundeep Bambolkar: No, it will be organic only. From our cash accruals, we'll repay the loans. And you will be surprised that even today, our loans are in the range of 8.5% to 8.75%. I agree for a company of Indoco's quality, they are slightly on the higher side. But we have borrowed as low as 4.75% to 5.5% when our performance was good and the rates were under control. So let's see, it's a function of global rates, rates by RBI and our performance, 3 in 1. I hope you got it.

  3. Question

    Raja Kumar: Yes, yes, I got it. But my worry is you've got too many things to take care. So the path to profitability is going to be a long cost is what I think.

    Answer, aditi panandikar

    Aditi Kare Panandikar: Yes, that is true. But like I said, since we understand that much of the problems this year are on account of a cause effect that we are in control of, as the product supply begins from the sites and we are able to bring in efficiency and control costs, we feel pretty confident that we'll be able to come out of it. But thank you for your concern.

    Answer, aditi panandikar

    Aditi Kare Panandikar: No, sufficient to say that it is quite high compared to the ethical business. And our immediate competitor spends close to 35% of their revenues on it, that much I know. So because Sensodyne is our biggest competitor and the largest player in the OTC segment for sensitivity toothpaste and their budgets are in that range. For us, partly, it's going to be a bit high. In the first year, I think we have spent close to 4 0%. But it will slowly come down as the sales go up. Yes, I said in the first couple of years, we were not expecting to break even because costs associated with advertising in this industry and product promotion are pretty high.

    Answer, aditi panandikar

    Page 15 of 19 Indoco Remedies Limited May 22, 2025 We have to remember, we are going from 25,000 dentists as customers to lakhs and lakhs of end users, supply chain wholesalers, grocers, retailers and the whole bank. So it's going to be a little bit high initially. But going forward, as the sales go up as a percentage, it should come under control. But this is a business which requires in the initial 2 to 3 years, heavy investment on brands. Vishal: Some sense, like you spent about INR16 crores on remediation. So would this spend be even larger than what you spend on remediation, the spend on your OTC brands?

    Answer, aditi panandikar

    Aditi Kare Panandikar: Yes, a larger number, certainly. Vishal: And this has all come up because of the strategy to do it OTC. Had you not probably thought of taking it OTC, you would have not spent this money at all?

    Answer, aditi panandikar

    Aditi Kare Panandikar: Yes. But our pace would have been limited to the scope of what they could in the sensitivity market, which is very limited in the ethical space. Vishal: So like any sense on how these -- what are the numbers are we getting to see on a monthly basis for these OTC brands?

    Answer, aditi panandikar

    Aditi Kare Panandikar: So as per Nielsen at tertiary level, our brand is growing at 18%, 19% in value. But there are many other parameters to be looked at when you're taking your product OTC. I mean, there are terms which are also new to me yet, but I'm getting familiar with them, things like weighted distribution, numerical distribution. So it's about creating reach. And from -- fundamentally, from a ll these numbers, it's looking good. It's not as if the past have not grown. They have shown a 10% growth, but we were expecting to do much better.

    Answer, aditi panandikar

    And today, we get 90% of -- 99% of our sales coming from -- through the chemist channel, whereas Sensodyne gets more than 35% coming from grocers where our presence is negligible. So it is 1-1 channel which we have to bring in, and that will open the market for us. The sensitivity market otherwise is INR500 crores, INR600 crore market. And the moment you go look at the sensitivity toothpaste market in Nielsen, it is an INR1,100 crore market. So it's a no-brainer that we had to go for this. Vishal: Okay. And you still continue to promote these as a prescription brand?

    Answer, aditi panandikar

    Aditi Kare Panandikar: Other variants of those. Not the same product. Page 16 of 19 Indoco Remedies Limited May 22, 2025 Vishal: But earlier, you used to get your sales as a prescription brand before kind of going OTC. Aditi Kare Panandikar: Yes, but the prescriptions continue because we realized that when we were purely ethical also, if a patient approaches the doctor and says that they are using an XYZ brand, the doctor does not stop them. So -- and incidentally, these toothpastes, if you look at the amount of prescriptions they were dependent on, it is very small compared to any other category. So this is a category which depends less on prescriptions and more on repeat purchase and end customer kind of thing. I hope that answers your question.

    Answer, aditi panandikar

    So our 2 ethical divisions in dental, they continue to carry variants of Sensodent -K and KF, but not these 2 products. So Sensodent-K Fast Relief and Sensodent-KF Cavity Protection is now purely under OTC. Vishal: And your price point is similar to the larger brands in the category? The GSK brands basically.

    Answer, aditi panandikar

    Aditi Kare Panandikar: Similar, yes, yes. Vishal: Okay. And you are not promoting this as a trade generic. You're promoting this as a direct to consumer brand.

    Answer, aditi panandikar

    Aditi Kare Panandikar: No, no, no trade generics for us. Not here. No. This is proper OTC. The setback we got this year has largely got to do with the channel change. Earlier in the ethical business, we were -- we had the system where a carry and forward agent would carry our product and the primary sale happened directly to the stockist. Here, we have super distributors who then sell out. So they are our business partners.

    Answer, aditi panandikar

    And with this shift where they have to sell more and more to wholesalers and distributors who are non-pharma or they have to sell to pharma distributors who ask from different terms. This phase has been a little bit tricky for us, but now it has all settled. So I feel confident going forward, we will see higher growth. Vishal: Would you also put this on these modern retail stores or you would restrict to pharmacists?

    Answer, aditi panandikar

    Aditi Kare Panandikar: We would have to because 30% of Sensodyne market is coming from modern trade. Vishal: So we will get to see your products on modern trade channel? Page 17 of 19 Indoco Remedies Limited May 22, 2025 Aditi Kare Panandikar: Yes, yes, gradually.

    Answer, aditi panandikar

    We already made small initiations. I believe we are on Amazon now, and it will come on others as well. But for us, because of predominantly the history with the ethical side, it will still stay very large in chemist and then we'll be adding grocers and then modern trade. It will go in that fashion. Vishal: Right. And just one final one, if I can. So the kind of the need to put so much of CapEx in the last few years, were we really kind of facing capacity constraints?

    Answer, aditi panandikar

    Aditi Kare Panandikar: A bit of both, more for the future. Vishal: Right. So just I'm asking this because we have kind of stretched our balance sheet in doing this. And...

    Answer, aditi panandikar

    Aditi Kare Panandikar: Yes. So you're asking me if we could have postponed anything. Vishal: Yes, that's what I meant.

    Answer, aditi panandikar

    Aditi Kare Panandikar: No, we are not planning to increase or decrease, but we are maintaining it at 5%. Even on a lower top line this year, in absolute terms, it has come down because we are now being a little bit more picky about the products we take up. How many because we have enough in our pipeline waiting to be filed. So considering the company is going through these times, we have decided to be very choosy about how much we invest in R&D for the next couple of years. But it will still stay at around 5% of top line. I don't think it will come below that.

Questions about this call

When was the Indoco Remedies Q4 FY25 earnings call transcript filed?
Indoco Remedies filed the transcript with the exchange on 26 May 2025. This page is built from that transcript.
What does this page list?
76 statements from the transcript across 11 topics, 31 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 13 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Indoco Remedies Q4 FY25 concall: what the company said · DalalOS